GVIRF 2021 Feedback

Content

Page 1 of 3

Question Title

* 1. Which Block did you attend?

Block 1

Block 2

Both Blocks

Question Title

* 2. Please rate the Plenary sessions you attended.

	Excellent	Very good	Good	Fair	Poor
Keynote: Anthony Fauci	Keynote: Anthony Fauci Excellent	Keynote: Anthony Fauci Very good	Keynote: Anthony Fauci Good	Keynote: Anthony Fauci Fair	Keynote: Anthony Fauci Poor
Keynotes: Bill Gates and Anuradha Gupta	Keynotes: Bill Gates and Anuradha Gupta Excellent	Keynotes: Bill Gates and Anuradha Gupta Very good	Keynotes: Bill Gates and Anuradha Gupta Good	Keynotes: Bill Gates and Anuradha Gupta Fair	Keynotes: Bill Gates and Anuradha Gupta Poor
Keynote: Soumya Swaminathan	Keynote: Soumya Swaminathan Excellent	Keynote: Soumya Swaminathan Very good	Keynote: Soumya Swaminathan Good	Keynote: Soumya Swaminathan Fair	Keynote: Soumya Swaminathan Poor
P1: Epidemic and Pandemic Preparedness and Response	P1: Epidemic and Pandemic Preparedness and Response Excellent	P1: Epidemic and Pandemic Preparedness and Response Very good	P1: Epidemic and Pandemic Preparedness and Response Good	P1: Epidemic and Pandemic Preparedness and Response Fair	P1: Epidemic and Pandemic Preparedness and Response Poor
P2: HIV, TB, and Malaria Vaccine Update	P2: HIV, TB, and Malaria Vaccine Update Excellent	P2: HIV, TB, and Malaria Vaccine Update Very good	P2: HIV, TB, and Malaria Vaccine Update Good	P2: HIV, TB, and Malaria Vaccine Update Fair	P2: HIV, TB, and Malaria Vaccine Update Poor
P3: Shaping the Future: Equitable Access for All	P3: Shaping the Future: Equitable Access for All Excellent	P3: Shaping the Future: Equitable Access for All Very good	P3: Shaping the Future: Equitable Access for All Good	P3: Shaping the Future: Equitable Access for All Fair	P3: Shaping the Future: Equitable Access for All Poor

Question Title

* 3. Please rate the workshops you attended.

	Excellent	Very good	Good	Fair	Poor
W1: Innovations in Vaccine Manufacturing	W1: Innovations in Vaccine Manufacturing Excellent	W1: Innovations in Vaccine Manufacturing Very good	W1: Innovations in Vaccine Manufacturing Good	W1: Innovations in Vaccine Manufacturing Fair	W1: Innovations in Vaccine Manufacturing Poor
W2: Emerging Platforms	W2: Emerging Platforms Excellent	W2: Emerging Platforms Very good	W2: Emerging Platforms Good	W2: Emerging Platforms Fair	W2: Emerging Platforms Poor
W3: Innovation in Vaccination	W3: Innovation in Vaccination Excellent	W3: Innovation in Vaccination Very good	W3: Innovation in Vaccination Good	W3: Innovation in Vaccination Fair	W3: Innovation in Vaccination Poor
W4: Controlled Human Infection Models	W4: Controlled Human Infection Models Excellent	W4: Controlled Human Infection Models Very good	W4: Controlled Human Infection Models Good	W4: Controlled Human Infection Models Fair	W4: Controlled Human Infection Models Poor
W5: New and Improved Vaccines on the Horizon	W5: New and Improved Vaccines on the Horizon Excellent	W5: New and Improved Vaccines on the Horizon Very good	W5: New and Improved Vaccines on the Horizon Good	W5: New and Improved Vaccines on the Horizon Fair	W5: New and Improved Vaccines on the Horizon Poor
W6: Vaccine Development to Access	W6: Vaccine Development to Access Excellent	W6: Vaccine Development to Access Very good	W6: Vaccine Development to Access Good	W6: Vaccine Development to Access Fair	W6: Vaccine Development to Access Poor
W7: Immune Responses over the Life Course	W7: Immune Responses over the Life Course Excellent	W7: Immune Responses over the Life Course Very good	W7: Immune Responses over the Life Course Good	W7: Immune Responses over the Life Course Fair	W7: Immune Responses over the Life Course Poor
W8: Prioritizing Vaccine R&D	W8: Prioritizing Vaccine R&D Excellent	W8: Prioritizing Vaccine R&D Very good	W8: Prioritizing Vaccine R&D Good	W8: Prioritizing Vaccine R&D Fair	W8: Prioritizing Vaccine R&D Poor
W9: Building and Sustaining Uptake	W9: Building and Sustaining Uptake Excellent	W9: Building and Sustaining Uptake Very good	W9: Building and Sustaining Uptake Good	W9: Building and Sustaining Uptake Fair	W9: Building and Sustaining Uptake Poor

Question Title

* 4. How was the range of topics in GVIRF 2021?

Too few

Just right

Too many

Clear

i We adjusted the number you entered based on the slider’s scale.

Question Title

* 5. How was the level of detail in the presentations?

Too simple

Just right

Too detailed

Clear

i We adjusted the number you entered based on the slider’s scale.

Question Title

* 6. How valuable was GVIRF?

	Strongly agree	Agree	Neither agree or disagree	Disagree	Strongly disagree
GVIRF helped me understand global progress in vaccine and immunization research.	GVIRF helped me understand global progress in vaccine and immunization research. Strongly agree	GVIRF helped me understand global progress in vaccine and immunization research. Agree	GVIRF helped me understand global progress in vaccine and immunization research. Neither agree or disagree	GVIRF helped me understand global progress in vaccine and immunization research. Disagree	GVIRF helped me understand global progress in vaccine and immunization research. Strongly disagree
GVIRF identified ways to accelerate progress in vaccines and immunization.	GVIRF identified ways to accelerate progress in vaccines and immunization. Strongly agree	GVIRF identified ways to accelerate progress in vaccines and immunization. Agree	GVIRF identified ways to accelerate progress in vaccines and immunization. Neither agree or disagree	GVIRF identified ways to accelerate progress in vaccines and immunization. Disagree	GVIRF identified ways to accelerate progress in vaccines and immunization. Strongly disagree
What I learned at GVIRF will help me in my work.	What I learned at GVIRF will help me in my work. Strongly agree	What I learned at GVIRF will help me in my work. Agree	What I learned at GVIRF will help me in my work. Neither agree or disagree	What I learned at GVIRF will help me in my work. Disagree	What I learned at GVIRF will help me in my work. Strongly disagree
GVIRF was a valuable networking opportunity.	GVIRF was a valuable networking opportunity. Strongly agree	GVIRF was a valuable networking opportunity. Agree	GVIRF was a valuable networking opportunity. Neither agree or disagree	GVIRF was a valuable networking opportunity. Disagree	GVIRF was a valuable networking opportunity. Strongly disagree

Question Title

* 7. Overall, how would you rate the event?

Excellent

Very good

Good

Fair

Poor

GVIRF 2021 Feedback

Content

Question Title

* 1. Which Block did you attend?

Question Title

* 2. Please rate the Plenary sessions you attended.

Question Title

* 3. Please rate the workshops you attended.

Question Title

* 4. How was the range of topics in GVIRF 2021?

Question Title

* 5. How was the level of detail in the presentations?

Question Title

* 6. How valuable was GVIRF?

Question Title

* 7. Overall, how would you rate the event?

Question Title

* 8. What would you like to see more of in the next GVIRF?

Question Title

* 9. What would you like to see less of in the next GVIRF?